pfizer back in town - tacere last paper, page-3

I am only a layman but my reading of this is that the whole process of how TT-034 shrna's work is far more complex than was first thought. That said it would appear that this complexity works in favour of TT-034 and contradicts some of the work published by Dr Mark Kay.

I think this research should give us even more reasons to be confident in TT-034.

Furthermore, the continued involvement of Pfizer and the involvement of the Welcome Trust shows that it is not only BLT shareholders who have a vested interest in the outcome of the TT-034 trial. All good stuff.